Hikma Pharmaceuticals Plc
11 September 2007
Hikma Pharmaceuticals PLC - LTIP Awards
LONDON, 11 September 2007: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
announces that the Remuneration Committee has made the following awards under
the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the 'LTIP') to
Directors/Persons Discharging Managerial Responsibility ('PDMRs') of the
Company.
Awards were made on 10 September 2007 at a price of £4.1225 per ordinary share
as follows:-
Name of PDMR Number of Shares awarded under the LTIP
Said Darwazah 100,000
Mazen Darwazah 50,000
The shares subject to the LTIP awards will only be released to the participants
in three years time, subject to their continued employment and the satisfaction
of the comparative Total Shareholder Return ('TSR') performance target.
Participants will only receive the full benefit of their share incentives if TSR
performance against the Comparator Group is at least at the upper quartile.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles +44 20 7399 2760
Company Secretary
Susan Ringdal +44 20 7399 2760
Investor Relations Director
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: 'Branded', 'Injectables' and 'Generics'.
Hikma's operations are based principally in the Middle East and North Africa
('MENA') region, where it is a market leader and sells across 17 countries, the
United States and Europe. In 2006, the Group achieved revenues of $317 million
(2005 $262 million) and profit attributable to shareholders was $55 million
(2005 $44 million). At 30 June 2007, the Group had over 2,700 employees. For
news and other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.